Natural Alternatives International, Inc. · NASDAQ:NAII

Natural Alternatives International — Investor Presentation (September 2026)

27 slides from Natural Alternatives International's investor presentation, September 2026

  1. Slide 1: Natural Alternatives International, Inc. Investor Presentation

    Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition. Natural Alternatives International, Inc. Investor Presentation September 2026 Nasdaq: NAII

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements reflect Natural Alternatives International, Inc.’s (the Company’s) current views about future events and financial performance b

  3. Slide 3: Regulation G

    Regulation G In addition, in order to assist you with period -over-period comparisons on a consistent and comparable basis, our presentation includes certain non-US GAAP information. This information excludes certain non-cash expenses, certain cash income and expense items related to our foreign cur

  4. Slide 4: Company Snapshot

    Company Snapshot NAII is the only pure-play public company that offers global formulation and manufacturing of customized nutritional supplements along with marketing branded and patented products Contract Manufacturing We provide private-label contract manufacturing services to companies that marke

  5. Slide 5: Company Strengths

    Company Strengths Multi-Continent Contract Manufacturing Facilities • Custom product formulation • State-of-the-art manufacturing facilities • Broad material acquisition & analysis • Certified in-house laboratory capabilities • Multiple packaging configuration capabilities In-House Brand Leveraging

  6. Slide 6: Company Strengths

    Company Strengths Growth Drivers From Organic Initiatives And Complementary Acquisitions • Expand existing customer products, base and channels • Expand in-house brands • Complementary acquisitions Strong Balance Sheet & Capacity To Support Growth Objectives • FY26 net sales of $142.5 million • Work

  7. Slide 7: Executive Management Team

    Executive Management Team Mark A. LeDoux CEO and Chairman of the Board of Directors Mr. LeDoux founded Natural Alternatives International (NAI) in 1980. With over 45 years of experience since joining the nutritional supplements industry in 1975, Mr. LeDoux is considered a highly regarded leader and

  8. Slide 8: Executive Management Team

    Executive Management Team Kenneth E. Wolf President, Chief Operating Officer & Principal Accounting Officer Mr. Wolf joined NAI in February 2008 as Chief Financial Officer, was promoted to Chief Operating Officer in June 2010 and has served as NAI’s President since October 2015. Mr. Wolf is responsi

  9. Slide 9: Overview – Capabilities

    Overview – Capabilities Global Production • Up to 17 million capsules and 11 million tablets daily capacity • Up to 500,000 bottles finished product daily capacity • Highly sophisticated in-house laboratories Packaging • Warehousing – 5,400+ pallet capacity • HDPE/PP Bottles Regulatory • Full Label

  10. Slide 10: Overview – Contract Manufacturing

    Overview – Contract Manufacturing Product Formulation • Custom formulations • In-house science teams • Clinical study design and support • In-house product stability testing capabilities Material Acquisition and Analysis • Global raw material sourcing expertise • Transparency and tracking of materia

  11. Slide 11: Overview – Patent & Trademark Licensing

    Overview – Patent & Trademark Licensing In-house brand expansion leveraging our proprietary ingredients: CarnoSyn® instant-release beta-alanine powder, SR CarnoSyn® sustained-release beta-alanine tablets, CarnoSyn® 4X high-bioavailability, paresthesia-free beta-alanine powder, and TriBsyn® carnosine

  12. Slide 12: Worldwide Operations and Market Reach

    Worldwide Operations and Market Reach NAI’s global footprint and scope facilitates greater opportunities and more dynamic client engagement Manno, Switzerland Carlsbad, CA Vista, CA NAI Offices and Operating Centers Primary Markets 12

  13. Slide 13: Get To Know NAI

    Get To Know NAI Welcome To NAI A personal welcome from founder & CEO Mark LeDoux Discover The NAI Difference The proven leader in custom formulation and contract manufacturing 13

  14. Slide 14: Accreditations

    Accreditations Industry leading accreditations and certification demonstrate our commitment to quality and are a strong barrier to entry Domestic (NAI) International (NAIE) Good Manufacturing Practices (cGMPs) (21 CFR 111) compliant – SwissMedic GMP certified – site registered and licensed FDA Inspe

  15. Slide 15: Industry Trends

    Industry Trends We will benefit from growing consumer interest in health and wellness 87% 66% 80% 87% - of consumers typically 66% - of consumers say 80% - of consumers who say use some type of vitamin, supplements are an supplements are an important mineral, or supplement1 important part of their p

  16. Slide 16: US Supplement Market Forecast

    US Supplement Market Forecast Supplement sales growth remains strong growing 4.4% to $64.4B in 2023; Supplement industry on track to approach $80B by 2027 and a CAGR of 5.2% between 2023 and 2027. SOURCE: Nutrition Business Journal: State of the Supplement Industry 2024 Inside the Bottle Summit 16

  17. Slide 17: Financial Performance and Growth Objectives

    Financial Performance and Growth Objectives 17

  18. Slide 18: Historical Revenue and Adjusted EBITDA

    Historical Revenue and Adjusted EBITDA Sales continue to rebound after the post COVID correction and FY24 rebalancing of supply and demand after peak sales in FY22. These reductions were partially offset by new products from existing customers and new customer acquisitions throughout FY25 and FY26.

  19. Slide 19: Historical Sales By Channel

    Historical Sales By Channel $180 Millions $160 9% 6% $140 5% 23% 6% $120 41% 7% 26% 43% $100 18% $80 $60 68% 75% 68% $40 53% 52% $20 $- FY22 FY23 FY24 FY25 FY26 Direct Sales Retail Patent & Trademark Licensing 19

  20. Slide 20: Investment Thesis

    Investment Thesis • Our available Global capacity is ~65% after USA consolidation leading to a more efficient, cost-effective footprint. • New high-capacity blender came online January 2022 in our Vista, CA facility increasing our overall product blending capacity in the USA by ~30% • Positioned to

  21. Slide 21: Investor Information

    Investor Information Stock Symbol: NASDAQ: NAII Company website: http://www.nai-online.com Company Headquarters: 1535 Faraday Avenue Carlsbad, CA 92008 Investor Relations Contacts Kenneth Wolf President & Acting Chief Financial Officer 760-736-7700 investor@nai-online.com 21

  22. Slide 22: Appendix

    Appendix Investor Relations Info 22

  23. Slide 23: Historical Segment Performance

    Historical Segment Performance In thousands Fiscal Year ended June 30, 2023 2024 2025 2026 * Revenue Private Label Contract Manufacturing $ 145,294 $ 105,358 $ 121,779 $ 134,615 Patent & Trademark Licensing $ 8,721 $ 8,438 $ 8,081 $ 7,900 Total Revenue $ 154,015 $ 113,796 $ 129,860 $ 142,515 Income

  24. Slide 24: Condensed Consolidated Statements of Operations

    Condensed Consolidated Statements of Operations In thousands, except per share data (Unaudited) Three Months Ended Year Ended June 30, June 30, 2026 2025 2026 2025 NET SALES $ 34,508 100.0% $ 33,866 100.0% $ 142,515 100.0% $ 129,860 100.0% Cost of goods sold 32,782 95.0% 30,331 89.6% 133,518 93.7% 1

  25. Slide 25: Condensed Consolidated Balance Sheets

    Condensed Consolidated Balance Sheets In thousands June 30, June 30, 2026 2025 ASSETS Cash and cash equivalents $7,388 $12,325 Restricted cash 86 - Accounts receivable, net 20,650 14,644 Inventories, net 30,753 24,871 Other current assets 6,557 7,436 Total current assets 65,434 59,276 Property and e

  26. Slide 26: Adjusted EBITDA Reconciliation (Non-US GAAP)

    Adjusted EBITDA Reconciliation (Non-US GAAP) Natural Alternatives International, Inc. Adjusted EBITDA - Non-US GAAP Reconciliation (In Thousands) (Unaudited) FY22 FY23 FY24 FY25 FY26 Net Income (Loss) $10,712 $2,522 ($7,216) ($13,576) ($20,695) Interest Income - (33) (176) (168) (50) Interest Expens

  27. Slide 27: Thank You

    Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition. Thank You www.nai-online.com Nasdaq: NAII

Natural Alternatives International — Investor Presentation (September 2026) on 6ix